Tuesday, April 8, 2025, 2:00 pm EDT
Individuals with chronic PTSD critically need more effective and tolerable treatments, especially those who have more severe and persistent symptoms. Dr. Adriana Feder will present results of the first open-label clinical trial combining a course of repeated ketamine infusions with a brief, evidence-based psychotherapy for PTSD called written exposure therapy (WET). This pilot trial will be explained in the context of prior ketamine studies for PTSD, along with a discussion of potential underlying psychobiological mechanisms that may be at play.
Please use #BBRFWebinar when sharing or posting about our Meet the Scientist Webinars on social media.
Sign up for other upcoming webinars.
View past webinar recordings.
Presented by
Icahn School of Medicine at Mount Sinai
2015 Independent Investigator Grant
2002 Young Investigator Grant
Dr. Adriana Feder is Professor of Psychiatry, Director of the Trauma and Resilience Program, and Associate Director for Research at the World Trade Center Mental Health Program at the Icahn School of Medicine at Mount Sinai. She is also a senior investigator at the Depression and Anxiety Center for Discovery and Treatment. Her research spans clinical, epidemiological and translational studies of resilience and posttraumatic stress in a range of trauma-exposed populations.
Dr. Feder's research focuses on the development of novel treatment interventions for PTSD and related disorders. Her research has significantly contributed to the development of ketamine as a treatment for PTSD, including the first published randomized controlled trials of single and repeated intravenous ketamine infusions for PTSD, as well as the first published neuroimaging study of ketamine for PTSD.
Moderated by
Brain & Behavior Research Foundation
Jeffrey Borenstein, M.D., serves as the President & CEO of the Brain & Behavior Research Foundation, the largest private funder of mental health research grants. Dr. Borenstein developed the Emmy-nominated public television program “Healthy Minds,” and serves as host and executive producer of the series. The program, broadcast nationwide, is available online, and focuses on topics in psychiatry in order to educate the public, reduce stigma and offer a message of hope. Dr. Borenstein served as Editor-in-Chief of Psychiatric News, the newspaper of the American Psychiatric Association from 2012 - 2023.
Dr. Borenstein is a Fellow of the New York Academy of Medicine and serves as the Chair of the Section of Psychiatry at the Academy. He also has served as the President of the New York State Psychiatric Association. Dr. Borenstein earned his undergraduate degree at Harvard and his medical degree at New York University.
